ResAppDx empowers clinicians to remotely assess respiratory disease with confidence

    Coviu has partnered with ResApp Health to facilitate remote respiratory testing using the ResAppDx app to help clinicians assess a patient’s respiratory symptoms and accurately diagnose their illness.








    Remote respiratory smartphone testing

    Clinically validated, TGA approved medical device

    Instant Results

    Patients take the ‘cough test’ using the ResAppDx app to aid you in your diagnosis of common respiratory diseases.

    Results proven in large Australian clinical studies. Read our scientific publications.

    Analysis report available during the session to help you confidently assess patient’s symptoms.


    Remote Respiratory Testing for Patients







    Symptom Check

    Perform Respiratory Cough Test

    Join the Call

    Patients are asked if they are experiencing these symptoms: fever, coughing, difficulty breathing, shortness of breath, runny nose, sore throat.

    Patients take the test using the ResAppDx app to capture five coughs.
    Their coughs are instantly analysed.

    Patients will then speak with their doctor to discuss the test results.


    Frequently Asked Questions 

    What can ResAppDx aid in the diagnosis of?

    ResAppDx can assist clinicians in the diagnosis of lower respiratory tract disease, pneumonia, asthma / reactive airway disease exacerbations, COPD exacerbations*, croup and bronchiolitis (2 years and younger).

    *Available on iOS only

    How do I enable ResAppDx Respiratory Test add-on?

    Head to the Coviu Add-on Marketplace and install the ResAppDx Respiratory Test add-on.

    How much does the ResAppDx Respiratory Test add-on cost?

    There is no additional cost to the clinic. The test is funded by the patient. 

    What happens after the ResAppDx Respiratory Test add-on is enabled?

    Once the add-on is installed, a symptom and device check will appear for all your patients who receive the email link to join your call. Patients who indicate that they are experiencing respiratory related symptoms will be guided to download the ResAppDx app and complete the test.

    To patients, the ResAppDx Respiratory Test is referred to as a ‘cough test’.

    Who can take the test?

    Patients who are 29 days or older.

    How much does the respiratory test cost for patients?

    The patient will be charged $11.00 per cough test.

    Medicare does not cover the cost of this testing.

    When does the patient take the respiratory cough test?

    The patient takes the cough test prior to the appointment (no earlier than one hour before the appointment). The results will be available to you (the Clinician) at the start of the session. This will allow more time spent with your patient discussing the results and treatment advice.  

    Does the patient have to have coughing symptoms to take the test?
    If the patient is experiencing short of breath, difficulty breathing, sore throat, runny nose or fever it is recommended that they take the cough test. The patient will need to produce involuntary coughs so that the app can capture the sounds from their lower airways.
    What is in the ResAppDx Analysis Report?
    The ResAppDx Analysis Report provides an indication, yes or no, for each disease tested, based on the patient’s age, symptoms and cough sounds. Watch the ‘ResAppDx Telehealth How it Works for Clinicians’ video for more information. 
    Does the patient receive the ResAppDx Analysis Report?

    No. The ResAppDx Analysis Report is only made available to the clinician conducting the telehealth consultation. It is available in the ResAppDx respiratory drawer in the session. 

    Where can I review the clinical performance for ResAppDx?

    Please refer to the Instructions for Use for more information. This will be available in theesAppDx Analysis Report.

    For more information on scientific presentations and publications visit

    What smartphones are compatible with ResAppDx?

    The ResAppDx app is compatible with iPhone (except iPhone 12 models) and Samsung Galaxy S9, S10 and S20 (except the Plus and Ultra variants).

    Disclaimer: Only indicated for use on patients aged 29 days and older. The result of the test should not be used as a sole diagnosis. The result should be used as part of an overall clinical assessment of the patient. Please refer to the Instructions for Use for information on interpreting the results and the clinical performance of ResAppDx. ResAppDx is listed on the Australian Register of Therapeutic Goods (ARTG). Always follow and read the Instructions for Use.

    Powered by